Literature DB >> 6202959

The agonistic and antagonistic actions of estriol.

J H Clark, B M Markaverich.   

Abstract

Estriol is a short acting estrogen, and as such, displays both agonistic and antagonistic properties, when it is injected in saline solution. These are predictable attributes of any short acting agonist if one considers the basic pharmacology of receptor ligand binding interactions. That is, short acting hormones or drugs occupy receptor sites for protracted time periods and, although they stimulate responses, these are of short duration. However, when estriol is administered in continuous fashion the estrogen receptor is occupied for long periods of time and full estrogenic responses are observed, and there is no antagonism of estradiol action. The purpose of this paper is to review the work that leads to the above conclusion and to discuss our more recent work on the relationship between estrogen receptor binding and the stimulation of type II estrogen binding sites.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202959     DOI: 10.1016/0022-4731(84)90011-6

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  9 in total

1.  Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin.

Authors:  Kevin Shoulars; Mary Ann Rodriguez; Trellis Thompson; Barry M Markaverich
Journal:  J Steroid Biochem Mol Biol       Date:  2009-10-27       Impact factor: 4.292

Review 2.  The role of lipoxin A4 in endometrial biology and endometriosis.

Authors:  G O Canny; B A Lessey
Journal:  Mucosal Immunol       Date:  2013-03-13       Impact factor: 7.313

3.  Estrogens and cell death in murine uterine luminal epithelium.

Authors:  J W Pollard; J Pacey; S V Cheng; E G Jordan
Journal:  Cell Tissue Res       Date:  1987-09       Impact factor: 5.249

4.  Molecular mechanisms of estrogen action in female genital tract development.

Authors:  Myles H Alderman; Hugh S Taylor
Journal:  Differentiation       Date:  2021-02-24       Impact factor: 3.880

5.  Estrogenic activity of bisphenol A and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane (HPTE) demonstrated in mouse uterine gene profiles.

Authors:  Sylvia C Hewitt; Kenneth S Korach
Journal:  Environ Health Perspect       Date:  2010-09-08       Impact factor: 9.031

6.  Development of phenotypic and transcriptional biomarkers to evaluate relative activity of potentially estrogenic chemicals in ovariectomized mice.

Authors:  Sylvia C Hewitt; Wipawee Winuthayanon; Brianna Pockette; Robnet T Kerns; Julie F Foley; Norris Flagler; Elizabeth Ney; Apichart Suksamrarn; Pawinee Piyachaturawat; Pierre R Bushel; Kenneth S Korach
Journal:  Environ Health Perspect       Date:  2015-01-09       Impact factor: 9.031

Review 7.  Gender and sex hormones in multiple sclerosis pathology and therapy.

Authors:  Arnaud Nicot
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

8.  Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling.

Authors:  Rajesh Kumar; Anne-Catherine Clerc; Ilaria Gori; Ronan Russell; Chiara Pellegrini; Lerisa Govender; Jean-Christophe Wyss; Dela Golshayan; Geraldine O Canny
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

9.  Proteome-Wide Effect of 17-β-Estradiol and Lipoxin A4 in an Endometriotic Epithelial Cell Line.

Authors:  Jonathan A Sobel; Patrice Waridel; Ilaria Gori; Manfredo Quadroni; Geraldine O Canny
Journal:  Front Endocrinol (Lausanne)       Date:  2016-01-06       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.